Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Scientists recommend research on bacterial vaccine to prevent influenza

Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well, according to a new article in the Journal of Infectious Diseases co-authored by David M. Morens, M.D., senior advisor to the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Nov 2010

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010

Inviragen receives two grants to develop dengue and chikungunya vaccines

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, announced today that it has received two grants totaling $488,958 through the United States government's Qualifying Therapeutic Discovery Project Program.

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

Virus fighting just got a new boost

In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.

2 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo Company today announced results for its first quarter ended September 25, 2010.

2 Nov 2010

West third quarter gross profit increases $3.0 million to $74.7 million

West Pharmaceutical Services, Inc. today announced its financial results for the third quarter of 2010.

2 Nov 2010

Cold Spring Harbor Protocols features standard and cutting-edge imaging laboratory techniques

Imaging has rapidly become a defining tool of the current era in biological research. But finding the right method and optimizing it for data collection can be a daunting process, even for an established imaging laboratory. Cold Spring Harbor Protocols is one of the world's leading sources for detailed technical instruction for implementation of imaging methods, and the November issue features articles detailing standard and cutting-edge laboratory techniques.

2 Nov 2010

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

VaxInnate Corporation announced today that VAX125, its investigational prototype vaccine for seasonal flu, has been named one of the Top 10 Infectious Diseases Projects to Watch in 2011 by Elsevier Business Intelligence and the Windhover Conferences.

2 Nov 2010

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

PPACA program provides $733,438 grant to Inovio

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2 Nov 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.

1 Nov 2010

Child Life Program organizes Halloween celebration for children undergoing treatment

Once a year cartoon characters, fairy princesses and action heroes gather at St. Jude Children's Research Hospital as hundreds of employees work together to turn the hospital into a giant trick-or-treat trail for children battling cancer and other catastrophic diseases. The event spans buildings and floors throughout the campus in Memphis, Tenn.

1 Nov 2010

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Scientists recommend research on bacterial vaccine to prevent influenza

BioCryst receives $1.1 million in grants under QTDP program

Inviragen receives two grants to develop dengue and chikungunya vaccines

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Virus fighting just got a new boost

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Perrigo first quarter revenue increases 21% to record $641 million

West third quarter gross profit increases $3.0 million to $74.7 million

Cold Spring Harbor Protocols features standard and cutting-edge imaging laboratory techniques

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

Teva third quarter net sales increase 20% to $4.3 billion

New REACT medical trial for early diagnosis of lung cancer

PPACA program provides $733,438 grant to Inovio

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Child Life Program organizes Halloween celebration for children undergoing treatment

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in